Sriram Krishnaswami

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 939 citations · Full text

Medicine, Immunology, Pharmacology +13

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

Eun Bong Lee, Roy Fleischmann, Stephen Hall et al. · New England Journal of Medicine · 2014 · 774 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman et al. · The Lancet · 2013 · 720 citations

Medicine, Pharmacology, Pharmacotherapy +12

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann et al. · Arthritis & Rheumatism · 2013 · 582 citations

Medicine, Internal Medicine, Pharmacotherapy +14

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

Joel M. Kremer, Bradley J. Bloom, Ferdinand C. Breedveld et al. · Arthritis & Rheumatism · 2009 · 544 citations

Medicine, Pharmacology, Pharmacotherapy +14